The co-hosts continue their look at major MASH stories from the first half of 2025 and two co-authors from a recent Lancet article on advanced liver screening join Roger Green to discuss their article.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
This week’s Newsmaker is hepatologist and key opinion leader Naga Chalasani of Indiana University. He discusses a recent article his group published in Hepatology Communications titled Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting.
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
This conversation focuses on two patient-related issues: the importance of patient advocacy in removing biopsy from clinical trial designs and more generally, principles for patient-centric clinical trials.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Maru Rinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
